Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498

Status	RECRUITING
Phase	Phase 3
Sponsor	Incyte Corporation
Enrollment	600 participants

Key Eligibility Criteria

Inclusion (6)

- Ability to comprehend and willingness to sign a written ICF for the study.
- Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
- Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
- Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
- Willingness to avoid pregnancy or fathering children as defined in the protocol.

... and 1 more (see full listing online)

Exclusion (10)

- Had been permanently discontinued from study treatment during the parent study.
- Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
- Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
- Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
- Live, attenuated vaccine.

... and 5 more (see full listing online)

Locations (330 total)

Investigative Site US086, Birmingham, Alabama, United States
Investigative Site US098, Montgomery, Alabama, United States
Investigative Site US004, Phoenix, Arizona, United States
... and 327 more locations

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.